Northwest BiotherapeuticsNWBO
13F holders, Q2 2026 (June 30)8holders
0new positions
0sold out
$0.19avg. 13F price*
At the end of Q2 2026, 8 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Compass Financial Management LLC ($227K), Kelleher Financial Advisors ($149K) and VSM Wealth Advisory, LLC ($15K).
- Company
- Northwest Biotherapeutics
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 600,000 shares bought, net +600,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Compass Financial Management LLC | 0.03% | — | 1,215,500 | $227K |
| Kelleher Financial Advisors | 0.02% | Add +300.0% | 800,000 | $149K |
| VSM Wealth Advisory, LLC | 0.00% | No change | 80,574 | $15K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $11K |
| Ethos Financial Group, LLC | 0.00% | No change | 39,070 | $6K |
| Williams Jones Wealth Management, LLC. | 0.00% | No change | 25,000 | $5K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.